|
|
||||||||
Resistance to mefloquine in Plasmodium falciparum has begun to occur along the border of Thailand and Kampuchea. As a means of assessing the natural occurrence of mefloquine resistance, the admission and post-treatment parasite isolates from a mefloquine treatment failure were cloned and characterized. Clones from the admission isolate were susceptible to mefloquine in vitro (ID50 of 3.4 [25], G [95% CI] ng/ml) and showed a mixture of isozyme types for glucose phosphate isomerase (GPI types I and II). The post-treatment clones were resistant to mefloquine in vitro (ID50 of 17.3 [1323] ng/ml) with only one isozyme (GPI type I) detected. These observations suggest that under mefloquine pressure a resistant parasite population was selected in the patient, indicating that the potential for mefloquine resistance already exists in the indigenous P. falciparum gene pool. In addition, the mefloquine-resistant clones showed decreased susceptibility in vitro to halofantrine suggesting possible cross-resistance to this new antimalarial drug currently under development.
Accepted for publication June 24, 1985.
This article has been cited by other articles:
![]() |
A. L. Pickard, C. Wongsrichanalai, A. Purfield, D. Kamwendo, K. Emery, C. Zalewski, F. Kawamoto, R. S. Miller, and S. R. Meshnick Resistance to Antimalarials in Southeast Asia and Genetic Polymorphisms in pfmdr1 Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2418 - 2423. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Martin, A. Oduola, and W. Milhous Reversal of chloroquine resistance in Plasmodium falciparum by verapamil Science, February 20, 1987; 235(4791): 899 - 901. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |